Edition:
United States

Quest Diagnostics Inc (DGX.N)

DGX.N on New York Stock Exchange

101.49USD
19 Apr 2018
Change (% chg)

-- (--)
Prev Close
$101.49
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
290,553
52-wk High
$112.83
52-wk Low
$90.21

Latest Key Developments (Source: Significant Developments)

Genomic Vision Extends Its Collaboration With Quest Diagnostics​
Wednesday, 14 Mar 2018 02:31am EDT 

March 14 (Reuters) - GENOMIC VISION SA ::‍GENOMIC VISION EXTENDS ITS COLLABORATION WITH QUEST DIAGNOSTICS IN SPINAL MUSCULAR ATROPHY (SMA)​.‍IF SUCCESSFULLY, GENOMIC VISION WILL RECEIVE ROYALTIES FOR ANY TEST SERVICE INDEPENDENTLY DEVELOPED BY QUEST AS A RESULT OF RESEARCH​.  Full Article

Quest Diagnostics Reports Q4 Adjusted Earnings Per Share $1.40
Thursday, 1 Feb 2018 06:45am EST 

Feb 1 (Reuters) - Quest Diagnostics Inc ::QUEST DIAGNOSTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS; PROVIDES GUIDANCE FOR FULL YEAR 2018; INCREASES DIVIDEND 11% TO $0.50 PER QUARTER.Q4 REVENUES OF $1.94 BILLION, UP 4.1% VERSUS 2016.SEES ‍FULL YEAR 2018 REPORTED DILUTED EPS $5.42 TO $5.62​.Q4 DILUTED EPS OF $1.82 ON A REPORTED BASIS.SEES ‍FULL YEAR 2018 ADJUSTED DILUTED EPS EXCLUDING AMORTIZATION EXPENSE AND ETB $6.50 TO $6.70​.Q4 REVENUE VIEW $1.94 BILLION -- THOMSON REUTERS I/B/E/S.SEES ‍FULL YEAR 2018 REVENUES $7.70 BILLION TO $7.77 BILLION​.Q4 ADJUSTED EARNINGS PER SHARE $1.40.FY2018 REVENUE VIEW $7.91 BILLION -- THOMSON REUTERS I/B/E/S.SEES ‍FULL YEAR 2018 CAPITAL EXPENDITURES $350 MILLION TO $400 MILLION​.Q4 EARNINGS PER SHARE VIEW $1.38 -- THOMSON REUTERS I/B/E/S.‍IN 2018 COMPANY EXPECTS TO REALIZE APPROXIMATELY $180 MILLION IN TAX SAVINGS ON AN ADJUSTED BASIS​.‍BOARD OF DIRECTORS AUTHORIZED AN 11% INCREASE IN ITS QUARTERLY DIVIDEND FROM $0.45 TO $0.50 PER SHARE​.BOARD AUTHORIZED AN 11% INCREASE IN ITS QUARTERLY DIVIDEND TO $0.50 PER SHARE.  Full Article

Quest Diagnostics provides update on impact of 2018 Medicare payment rates
Monday, 20 Nov 2017 05:36pm EST 

Nov 20 (Reuters) - Quest Diagnostics Inc ::Quest Diagnostics provides update on impact of final 2018 Medicare payment rates for clinical laboratory tests.Quest Diagnostics Inc - ‍expects impact of final fee schedule rates under Protecting Access To Medicare Act​ (PAMA) to be about 4% in 2018.Quest Diagnostics Inc - ‍expects impact of final fee schedule rates under PAMA to be about 10% in 2019 and 2020.  Full Article

FDA approves Clinical Genomics, Quest Diagnostics Insure One
Monday, 13 Nov 2017 08:00am EST 

Nov 13 (Reuters) - Quest Diagnostics Inc :Clinical Genomics and Quest Diagnostics announce FDA 510(k) clearance of Insure® One™.Quest Diagnostics Inc- ‍insure One is expected to be commercially available in early 2018​.  Full Article

Quest Diagnostics acquires certain assets of California Laboratory Associates
Monday, 30 Oct 2017 06:45am EDT 

Oct 30 (Reuters) - Quest Diagnostics Inc :Quest Diagnostics acquires California Laboratory Associates.Quest Diagnostics Inc - ‍financial terms of agreement were not disclosed.​.Quest Diagnostics Inc - ‍it has acquired certain assets of California Laboratory Associates, a clinical lab network​.  Full Article

Advantage Capital Portfolio company Cleveland Heartlab acquired by Quest Diagnostics
Thursday, 19 Oct 2017 04:17pm EDT 

Oct 19 (Reuters) - Quest Diagnostics Inc :Advantage Capital Portfolio company Cleveland Heartlab, Inc acquired by Quest Diagnostics.‍cleveland Heartlab says Quest to maintain Cleveland Heartlab's clinic location in Cleveland's midtown area.  Full Article

Quest Diagnostics reports Q3 diluted eps of $1.15
Thursday, 19 Oct 2017 06:45am EDT 

Oct 19 (Reuters) - Quest Diagnostics Inc ::Quest Diagnostics reports third quarter 2017 financial results, updates 2017 financial guidance and reaffirms long term outlook.qtrly ‍adj earnings per share $1.39​.‍q3 reported diluted eps of $1.15​.Reports q3 revenue $1.93 billion.Reports q3 revenue up 2.4 percent.‍reaffirms long term outlook for 2017-2020​.‍2017 cash provided by operations remains at approximately $1.2 billion​.‍updates outlook for full year 2017 primarily due to financial impact of hurricanes and recently closed acquisitions in q3​.‍2017 reported revenues now expected to be approximately $7.71 billion​.‍continue to "urge" cms to delay implementation of protecting access to medicare act "to take time to get it right"​.‍2017 reported diluted eps now expected to be between $4.87 and $4.92​.2017 ‍adjusted diluted eps excluding amortization expense now expected to be between $5.62 and $5.67​.Fy2017 earnings per share view $5.63, revenue view $7.69 billion -- Thomson Reuters I/B/E/S.Q3 earnings per share view $1.35, revenue view $1.92 billion -- Thomson Reuters I/B/E/S.  Full Article

Quest Diagnostics to acquire Shiel Medical Laboratory from Fresenius Medical Care
Thursday, 28 Sep 2017 07:30am EDT 

Sept 28 (Reuters) - Quest Diagnostics Inc :Quest Diagnostics to acquire Shiel Medical Laboratory from Fresenius Medical Care.Quest Diagnostics Inc says financial terms were not disclosed..Says ‍transaction is structured as a purchase of assets.​.Quest Diagnostics Inc says transaction is expected to be completed in Q4 of 2017, subject to customary regulatory approvals.Quest Diagnostics - ‍Fresenius Medical Care's dialysis-related laboratory services business, Spectra Labs, is not affected by divestiture​.  Full Article

Quest Diagnostics provides update on impact to 3rd quarter financial results from hurricanes
Wednesday, 27 Sep 2017 04:15pm EDT 

Sept 27 (Reuters) - Quest Diagnostics Inc :Quest Diagnostics provides update on impact to third quarter financial results from hurricanes.Quest Diagnostics Inc- expects a reduction in revenues of about 1.5 pct due to recent hurricanes in Q3 2017.Quest Diagnostics Inc- expects a reduction in both reported EPS and adjusted diluted earnings per share of about $0.10 due to recent hurricanes in Q3.Quest diagnostics Inc- excluding anticipated impact of hurricanes in Q3, company reaffirms 2017 guidance provided on July 25, 2017.  Full Article

Oxford Immunotec announces update in patent infringement litigation
Wednesday, 27 Sep 2017 09:25am EDT 

Sept 27 (Reuters) - Oxford Immunotec Global Plc :Oxford Immunotec announces update in patent infringement litigation.Says ‍court denied company's motion​.Says ‍court further noted that if co "prevails at trial, it is likely that infringing aspects of qft plus will be permanently enjoined"​.Says ‍court believed company was not likely to suffer irreparable harm from qft-plus during few months remaining before trial​.  Full Article

BRIEF-Quest Diagnostics Says CEO Rusckowski's 2017 Total Compensation Was $10.35 Mln Vs $10.25 Mln In 2016 ‍​

* QUEST DIAGNOSTICS INC SAYS CEO STEPHEN H. RUSCKOWSKI'S 2017 TOTAL COMPENSATION WAS $10.35 MILLION VERSUS $10.25 MILLION IN 2016 – SEC FILING ‍​ Source text: (https://bit.ly/2uKsWVj) Further company coverage: